High-dose chemotherapy followed by CD34
High-dose chemotherapy followed by peripheral blood progenitor cell (PBPC) transplantation can offer prolonged disease-free survival for relapsed Hodgkin's disease and nonHodgkins lymphoma patients. 1 It has been proposed that contaminating lymphoma cells in the harvested peripheral blood collections may be responsible for relapse following transplantation. 2 Positive selection of the peripheral blood cells for CD34 ϩ progenitors may reduce the number of contaminating tumor cells while preserving hematopoietic engraftment. [3] [4] [5] However, the CD34 ϩ cell enrichment procedure, while reducing tumor burden, may compromise immunological reconstitution by depleting the grafts of mature T and B lymphocytes, thereby resulting in an increased number of opportunistic infections. [5] [6] [7] Several reports have shown that severe viral infections including cytomegalovirus (CMV) retinitis, adenovirus-associated hemorrhagic cystitis, fatal herpes pneumonitis, and severe cryptosporidiosis can occur after autologous CD34 ϩ cell enriched transplants. 6, 7 A recent study found a higher frequency of CMV disease in patients transplanted with the CD34 ϩ enriched PBPCs as compared to patients transplanted with unselected PBPCs. 8 We therefore compared infectious morbidity associated with CD34 ϩ enriched PBPC transplantation in lymphoma patients to those patients treated with an identical high-dose chemotherapy regimen but who received unmanipulated PBPCs. In this single institution study we determined that patients supported with CD34 ϩ enriched PBPCs had a higher 1 year infectious morbidity after transplantation.
Materials and methods
The records of lymphoma patients undergoing PBPC transplantation at the Ireland Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, were reviewed. Patients with relapsed, primary refractory (induction-failure), or high-risk non-Hodgkin's lymphoma or Hodgkin's disease were treated with high-dose carmustine, etoposide and cisplatin 1 and were supported using either CD34 ϩ enriched PBPCs (December 1996-March 1998) or unmanipulated PBPCs (1993 PBPCs ( -1998 . Patients were given CD34 ϩ enriched PBPC transplantation based on eligibility for clinical protocols. Eligibility was broad as described previously 4, 9 and between December 1996 and March 1998, 27 of 38 consecutive patients underwent autologous CD34 ϩ enriched PBSC transplantation. A total of ϩ enriched PBPC and 24 unmanipulated PBSC transplant patients had a minimum of 1 year of follow-up and were free of malignant disease recurrence and included in this analysis. The total leukocyte, absolute lymphocyte and monocyte counts were recorded from patient charts at approximate intervals of 3 weeks, 6 weeks, 6 months and 1 year post transplant. The records were reviewed for posttransplant complications following discharge from the initial hospitalization and limited to 1 year post transplantation. The demographic and clinical characteristics of the study patients are included in Table 1 . All patients achieved myeloid engraftment prior to discharge from hospital. 4 
Eligibility for transplantation
Patients were required to have an ECOG performance status of 0 or 1 and have adequate visceral organ function including: left ventricular ejection fraction at least 45% of predicted, no uncontrolled congestive heart failure or hypertension, no myocardial infarction in the previous 6 months, FEV1 and DLCO Ͼ50% of predicted, actual or calculated creatinine clearance Ͼ60 ml/min, ALT and AST Ͻ3 times normal, and no severe infections, or endocrine or neurologic disorders. Patients were excluded if they had: cumulative exposure to carmustine greater than 200 mg/m 2 ; cumulative bleomycin greater than 100 units/m 2 ; doxorubicin in excess of 550 mg/mg 2 ; evidence of active infection; or a history of another malignant disease within the past 5 years. Patients were not excluded for evidence of tumor on routine histologic staining of bilateral paraffin-embedded posterior iliac crest bone marrow biopsies.
Mobilization and collection of PBPC
As previously published, the mobilization regimen consisted of cyclophosphamide (4.0 g/m 2 ) intravenously over 3-6 h on the first day of mobilization along with mesna 3.0 g/m 2 in the cyclophosphamide dosing bag, then 500 mg every 3 h by mouth or by vein for eight doses. 4 Prednisone (2 mg/kg/day) was given orally for the first 4 days of mobilization. G-CSF (Amgen, Thousand Oaks, CA, USA) (10 g/kg/day) was given subcutaneously beginning between 36 and 48 h after the completion of cyclophos- phamide until a combined minimum collection of у2.0 ϫ 10 6 CD34 ϩ cells/kg was achieved.
Positive selection of CD34 ϩ cells from mobilized PBPC
As previously reported, harvested mononuclear cells from each leukaperesis collection were prepared and passed over the immunoaffinity column device (CEPRATE, SC System, Baxter, Deerfield, IL, USA) as directed by the manufacturer (CellPro, Bothell, WA, USA). Adsorbed CD34 ϩ cells were resuspended at 2 ϫ 10 7 cells/ml and frozen using a controlled-rate liquid nitrogen freezer in the presence of 7.5% (final concentration) dimethyl sulfoxide (DMSO; Sigma, St Louis, MO, USA). 4 
Clinical follow-up
Only patients closely followed in the Ireland Cancer Center (returned for follow-up approximately every 2 months) were included in this study. All patients were given antimicrobial prophylaxis with trimethoprim-sulfamethoxazole for up to 3-4 months post discharge from hospitalization for transplantation. Acyclovir or ciprofloxacin were not given as routine prophylaxis. In addition, vaccination with pneumococcus, tetanus, diptheria, haemophilus, and influenza B was not begun until 1 year post transplant.
Complications and infections occurring during the initial hospitalization while patients were neutropenic are not reported here. Patients lacking documentation of follow-up visits and those with documented disease relapse in the year following transplantation were excluded from analysis. Also, patients who received Rituximab (Genentech, South San Francisco, CA, USA), anti-B cell monoclonal antibody therapy, were excluded. Bacterial, viral, and fungal infections were defined either by clinical symptoms and response to treatment, or by confirmation with laboratory culture. Infections leading to sepsis and multi-organ failure, adult respiratory distress syndrome (ARDS) and death were included as one infectious event. Infections occurring in different anatomical locations concurrently were recorded as separate infections. Presumed infectious complications that had an unproven or unknown etiology were included in a 'presumed infectious complications' category. This included upper respiratory infections, flu-like illness, and unexplained fevers not related to malignancy.
Statistical methods
The Fisher's exact test was used to compare the frequency of infectious and non-infectious complications between the CD34 ϩ enriched transplant patients and the unmanipulated PBPC transplant patients.
Results

Demographics
Between December 1996 and March 1998, a total of 38 patients underwent high-dose chemotherapy and autologous PBSC transplantation. Seventy-one percent of those
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؉ cell transplant morbidity J Friedman et al 833 patients (27 of 38) were eligible for CD34 ϩ cell enrichment protocols and transplanted with CD34 ϩ enriched PBPCs only. Nineteen of 27 were eligible for evaluation of infectious complications. Five were ineligible due to relapse prior to 12 months post transplant, two had additional anti-B cell monoclonal antibody therapy and one had insufficient follow-up data. For the control group, we have randomly reviewed the clinical courses of 32 patients who underwent conventional autologous PBSC transplantation for lymphoma, out of 102 patients transplanted between 1993 and 1998. Twenty-four of 32 were eligible for evaluation of infectious complications. Three patients were ineligible due to relapse prior to 12 months, three had insufficient data, one had additional anti-B cell monoclonal antibody therapy and one died peritransplant prior to engraftment. The clinical characteristics of the study patients are summarized in Table 1 . The median age at transplantation was similar in both groups, as were the number of prior chemotherapy regimens. The group transplanted with unmanipulated PBPC contained greater numbers of females and patients treated with radiation.
Infectious complications
A statistically significantly increased number of patients with one or more infectious events was found in the CD34 ϩ transplant group compared with the PBPC group (14/19 vs 9/24, P Ͻ 0.01) ( Table 2) . Additionally, there were increased numbers of patients with two or more infectious events in the CD34 ϩ group (7/19 vs 2/24, P Ͻ 0.03). This difference was mostly on the basis of an increased incidence of bacterial infections observed in the CD34 ϩ group (10/19 in the CD34 ϩ group vs 5/24 in the PBPC group, P Ͻ 0.05). The greater numbers of viral infections and the presumed infections found in the CD34 ϩ group were not significantly different from those in the PBPC group. The one fungal infection observed, hepatosplenic candidiasis, occurred in the PBPC transplant group. A detailed documentation of the infectious complications in individual patients, including the type and timing of bacterial, viral, and fungal infections appears in Tables 3 and 4 . Infectious events occurred at a median of 4 months in the CD34 ϩ transplant patients and 5 months in the unmanipulated PBPC transplant. Sixty-nine percent of the infections in the Bone Marrow Transplantation CD34 ϩ selected patients occurred before 6 months, and 75% in the PBPC transplant patients. There were two infectious deaths in the CD34 ϩ group and none in the unmanipulated PBPC patients. Although this low event rate precludes a statistically significant conclusion, infectious deaths in lymphoma patients undergoing autologous PBPC transplantation is uncommon at our center. Therefore, this finding has substantial clinical significance.
Lymphocyte and monocyte counts
Peripheral blood lymphocyte and monocyte counts at 3 weeks, 6 weeks, 3 months and 1 year post transplant are shown in Figures 1 and 2 . There were no significant differences in mean lymphocyte and monocyte counts between study groups during the 12 months post transplant. There appeared to be a greater variability in counts of patients transplanted with CD34 ϩ enriched cells.
Discussion
We report a significant increase in the incidence of infectious complications in lymphoma patients transplanted using autologous CD34 ϩ enriched PBPCs compared to unmanipulated PBPCs within the first year after transplantation. Both patient groups had comparable demographics, and both groups received close follow-up. We found a statistically higher number of patients suffering from one or multiple late infections in the CD34 ϩ transplant group. Interestingly there was an increased incidence of bacterial infections but not of fungal and viral infections in the CD34 ϩ transplant patients. This finding may be due to low detection rate of viral infections as viral cultures are not routinely performed in these patients. There was only one documented fungal infection and the low event rate precludes meaningful comparison between cohorts.
The increased morbidity in the CD34 ϩ transplant patients may be attributable to either qualitative or quantitative differences in the reconstituted immune systems of the patients. Our study indicates that absolute lymphocyte and monocyte counts do not appear to be different between groups. Therefore, it is more likely that qualitative and quantitative differences in subsets of CD4 ϩ or CD8 ϩ lymphocytes may be responsible for the increase in the infection rate in this group. Studies investigating the lymphoid reconstitution of CD34 ϩ transplanted patients found fewer circulating B cells and CD4 ϩ T cells post transplant compared to that of unmanipulated PBPC patients. 10 Proper numbers and function of CD4 ϩ T cells are essential for the activation and maturation of B cells. It has also been demonstrated by reverse transcriptase-polymerase chain reaction amplification of the T cell receptor antigen-binding region (VDJ regions) that T cells in the CD34 ϩ enriched transplant patients had decreased diversity of their VDJ regions compared to those in the PBSC transplant group. These studies suggests that the CD34 ϩ enrichment process may result in both quantitative and qualitative deficiencies in a reconstituted immune system as compared to the immune system of patients reconstituted with the PBPC transplant. It is possible that a lower CD4 ϩ /CD8 ϩ ratio and/or fewer B lymphocytes could result in a clinically significant defect in immunity of the patients transplanted with CD34 ϩ cells. In addition, two studies found that PBPC collections of patients given chemotherapy have a decreased CD4 ϩ /CD8 ϩ ratio compared to the peripheral blood of normal volunteers. 11, 12 Additionally, the transplanted patients had increased suppressor T cell activity. 7 The addition of a further step in the processing of PBPC for transplantation, such as the CD34 ϩ enrichment process, may further alter the lymphoid reconstitution of autologous peripheral blood transplant patients.
In this report, we focused not on the initial transplant hospitalization but post transplant months 1-12, and were able to demonstrate a clinically significant increase in infectious morbidity and assess the risk long term. Patients transplanted with CD34 ϩ enriched cells may require increased infectious prophylaxis and closer monitoring than patients receiving PBPC alone. It may be necessary to prospectively examine B and CD4 ϩ , CD8 ϩ T lymphocyte engraftment and function, and the infectious complications in the CD34 ϩ cell enriched transplant patients as compared to PBPC. It is also necessary to determine the long-term risks of CD34 ϩ cell enriched transplants to determine their risk/benefit ratio. The small amount of benefit obtained by tumor purging may be lost in these patients if there is a significant infectious morbidity and mortality. Our clinical protocols were not designed to determine the efficacy of CD34 ϩ enrichment on overall outcome. In fact, with relatively small numbers of patients we were unable to demonstrate a significant difference in disease-free and overall survival of patients transplanted with CD34 ϩ enriched cells compared to conventional PBPC transplantation. The relative efficacy of this approach needs to be determined in phase III clinical trials, particularly in intermediate stage NHL and the impact of infectious morbidity and mortality on outcome should be evaluated.
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Additionally, newly developed anti-B cell or anti-T cell targeted therapies, designed to decrease tumor recurrence, may do so, but at the expense of delayed immune reconstitution and increased infections, particularly when combined with autologous transplantation.
In conclusion, autologous CD34 ϩ enriched PBPC transplantation in lymphoma patients is associated with increased infectious morbidity and mortality during the first year after transplantation. Autologous CD34 ϩ enriched PBPC transplantation should be performed within investigational clinical protocols, the excess risk of infection should be discussed prospectively with participating patients and long-term infection monitoring and prophylaxis should be considered.
